The business case for regulated AI turns on the cost of producing an outcome that the quality system can accept.
|Articles|May 25, 2022
Introduction to antibody libraries for display-based antibody discovery
Author(s)Curia
Protein engineering has greatly benefited by the advent of in vitro display platforms, where individual or large libraries of peptides or proteins are displayed on the surface of mammalian, yeast, or bacterial cells or even bacteriophage capsids. Learn more about the main principles of phage and yeast surface display platforms & how Curia can power your antibody discovery and engineering projects.
Related to this article
In October, FDA reorganized rare disease development around a fit-for-purpose framework and a new pathway for individualized gene editing. Regulators in Europe and the UK set out long-term plans for clinical trials, AI, and moving away from animal testing.
Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.
Structural modifications can improve peptide stability, solubility, and absorption to enable effective oral delivery.
The FDA approves VOCERYQ, the first DNA medicine, for RRP surgery reduction, raising plasmid, drug-device, and confirmatory trial manufacturing demands.
Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.
Subathra Ramamoorthy, Veranova, on how forced degradation and trace impurity profiling in potent APIs shape regulator-ready analytical methods.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Improving Oral Peptide Delivery Through Structural Modifications
3
Who Answers for Your Data? Building a Life Sciences Data Mesh
4
RRP Accelerated Approval: What VOCERYQ Means for Manufacturing Teams
5